Novavax
NVAX
$4.09
Share price
3.54%
Change (1 day)
-45.90%
Change (1 year)
Categories
Novavax (NVAX) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $2.51 B
According to Novavax's latest financial reports the company's total liabilities are $2.51 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Novavax - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $2.51 B | -13.08% |
| 2022-12-31 | $2.89 B | -1.22% |
| 2021-12-31 | $2.92 B | 206.55% |
| 2020-12-31 | $0.95 B | 166.11% |
| 2019-12-31 | $0.35 B | -4.51% |
| 2018-12-31 | $0.37 B | -7% |
| 2017-12-31 | $0.40 B | 1.09% |
| 2016-12-31 | $0.39 B | 328.24% |
| 2015-12-31 | $93.36 M | 101.3% |
| 2014-12-31 | $46.38 M | 45.45% |
| 2013-12-31 | $31.89 M | 44.27% |
| 2012-12-31 | $22.1 M | 73.69% |
| 2011-12-31 | $12.72 M | -19.42% |
| 2010-12-31 | $15.79 M | 0.9% |
| 2009-12-31 | $15.65 M | -49.73% |
| 2008-12-31 | $31.13 M | 10.31% |
| 2007-12-31 | $28.22 M | 1.26% |
| 2006-12-31 | $27.87 M | -19.74% |
| 2005-12-31 | $34.73 M | -22.33% |
| 2004-12-31 | $44.71 M | -7.27% |
| 2003-12-31 | $48.21 M | -2.46% |
| 2002-12-31 | $49.43 M | 24.76% |
| 2001-12-31 | $39.62 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $54.57 B | 2,070.60% | 🇨🇭 Switzerland |
 Pfizer PFE | $137.21 B | 5,357.04% | 🇺🇸 USA |
 AstraZeneca AZN | $64.79 B | 2,476.82% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $58.82 B | 2,239.52% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $2.40 B | -4.34% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $36.45 M | -98.55% | 🇺🇸 USA |
 Agenus
AGEN | $0.46 B | -81.61% | 🇺🇸 USA |
 NanoViricides NNVC | $0.95 M | -99.96% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.97 B | -61.32% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $1.17 B | -53.31% | 🇺🇸 USA |